AstraZeneca's Tozorakimab Meets Primary Endpoint in COPD Phase III Trial
AstraZeneca's biologics candidate, tozorakimab, met its primary endpoint in the Phase III MIRANDA trial for patients with COPD. The study demonstrated a statistically significant reduction in moderate-to-severe COPD exacerbations.
AstraZeneca announced today that its biologic medicine tozorakimab met its primary endpoint in the pivotal Phase III MIRANDA trial, evaluating the treatment of chronic obstructive pulmonary disease (COPD) in patients. The trial demonstrated a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations.
In the MIRANDA trial, patients received tozorakimab or placebo every two weeks as an add-on to their standard of care. The study enrolled patients with COPD who continued to experience moderate-to-severe exacerbations despite ongoing inhaled therapy. The drug candidate was generally well tolerated with a favorable safety profile, consistent with previous trials.
Tozorakimab is a monoclonal antibody targeting interleukin-33 (IL-33), a protein implicated in respiratory inflammation. By inhibiting IL-33 signaling, tozorakimab aims to reduce underlying inflammation and consequently lower the frequency of exacerbations, which can lead to serious health consequences including hospitalization or death.
These results follow previous announcements of positive data from the pivotal Phase III OBERON and TITANIA trials, where tozorakimab was investigated with a four-week dosing interval. AstraZeneca plans to submit the data to regulatory authorities and present it to the scientific community at an upcoming medical meeting. COPD is a progressive lung disease and the third leading cause of death globally.